• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ALX Oncology Holdings Inc.

    10/13/23 4:00:25 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALXO alert in real time by email
    SC 13G 1 schedule13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No.  __)*
     

     
    ALX Oncology Holdings Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock
     
     
    (Title of Class of Securities)
     

     
    00166B105
     
     
    (CUSIP Number)
     

     
    October 3, 2023
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    1
    Names of Reporting Persons.
     
    Cormorant Global Healthcare Master Fund, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Cayman Islands

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    2,630,000 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    2,630,000 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,630,000 shares
     
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    5.28%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)
     


    1
    Names of Reporting Persons.
     
    Cormorant Global Healthcare GP, LLC
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    2,630,000 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    2,630,000 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,630,000 shares
     
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    5.28%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    OO (Limited Liability Company)
     

    1
    Names of Reporting Persons.
     
    Cormorant Private Healthcare Fund II, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    512,079 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    512,079 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    512,079 shares
     
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    1.03%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)
     


    1
    Names of Reporting Persons.
     
    Cormorant Global Healthcare GP II, LLC
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    512,079 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    512,079 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    512,079 shares
     
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    1.03%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    OO (Limited Liability Company)
     

    1
    Names of Reporting Persons.
     
    Cormorant Asset Management, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    3,142,079 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    3,142,079 shares
    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,142,079 shares
     
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    6.31%
    Refer to Item 4 below.
     


    1
    Names of Reporting Persons.
     
    Bihua Chen
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    3,142,079 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    3,142,079 shares
    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,142,079 shares
     
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    6.31%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    IN (Individual)
     

    Item 1.
    (a)
    Name of Issuer
     
    ALX Oncology Holdings Inc.
     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    323 Allerton Avenue, South San Francisco, California 94080

    Item 2.
    (a)
    Name of Person Filing
     

    Cormorant Global Healthcare Master Fund, LP
    Cormorant Global Healthcare GP, LLC
    Cormorant Private Healthcare Fund II, LP
    Cormorant Private Healthcare GP II, LLC
    Cormorant Asset Management, LP
    Bihua Chen
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    200 Clarendon Street, 52nd Floor
    Boston, MA 02116
     
    (c)
    Citizenship
     
     
    Cormorant Global Healthcare Master Fund, LP - Cayman Islands
    Cormorant Global Healthcare GP, LLC - Delaware
    Cormorant Private Healthcare Fund II, LP - Delaware
    Cormorant Private Healthcare GP II, LLC - Delaware
    Cormorant Asset Management, LP - Delaware
    Bihua Chen - United States
     
    (d)
    Title of Class of Securities
     
    Common Stock
     
    (e)
    CUSIP Number
     
    00166B105


    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)
    [ ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)
    [ ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)
    [ ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)
    [ ]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

    Item 4.
    Ownership***
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)          Amount Beneficially Owned***

    The information set forth in Row 9 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(a) for each such Reporting Person.

    (b)          Percent of Class***

    The information set forth in Row 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.

    (c)          Number of shares as to which such person has: ***

    (i)          sole power to vote or to direct the vote

    (ii)          shared power to vote or to direct the vote

    (iii)          sole power to dispose or to direct the disposition of

    (iv)          shared power to dispose or to direct the disposition of

    The information set forth in Rows 5 through 8 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(c) for each such Reporting Person.

    *** Shares reported herein for Cormorant Asset Management, LP represent shares which are beneficially owned by Cormorant Global Healthcare Master Fund, LP (the “Master Fund”) and Cormorant Private Healthcare Fund II, LP (“Fund II”), as reported herein. Cormorant Global Healthcare GP, LLC and Cormorant Private Healthcare GP II, LLC serve as the general partners of the Master Fund and Fund II, respectively. Cormorant Asset Management, LP serves as the investment manager to the Master Fund and Fund II. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC and Cormorant Private Healthcare GP II, LLC and the general partner of Cormorant Asset Management, LP. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein.
    The percentages reported herein with respect to the Reporting Persons’ holdings are calculated based upon: (i)  a statement in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, as filed with the Securities and Exchange Commission on August 10, 2023, that there were 41,151,819 shares of Common Stock of the Issuer outstanding as of August 3, 2023; (ii) a statement in a prospectus supplement dated October 4, 2023, as filed by the Issuer with the Securities and Exchange Commission on October 6, 2023, relating to the offer by the Issuer of 8,663,793 shares of Common Stock (including shares issuable pursuant to an option granted to the underwriters of such offering); and (iii) a statement in a press release of the Issuer, dated October 10, 2023, stating that all of such offered shares had been issued.

    Item 5.
    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    Exhibits                          Exhibit
    99.1                  Joint Filing Agreement by and among the Reporting Persons.

    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
    October 13, 2023

     
    CORMORANT GLOBAL HEALTHCARE MASTER
     
    FUND, LP

     
    By:
    Cormorant Global Healthcare GP, LLC
     
     
    its General Partner
     
     
     
     
    By:
    /s/ Bihua Chen
     
    Bihua Chen, Managing Member
     
     
     
     
    CORMORANT GLOBAL HEALTHCARE GP, LLC
     
     
     
     
    By:
    /s/ Bihua Chen
     
    Bihua Chen, Managing Member
     
     
     
     
    CORMORANT PRIVATE HEALTHCARE FUND II, LP
     
    By:
    Cormorant Private Healthcare GP II, LLC
       
    its General Partner
         
     
    By:
    /s/ Bihua Chen
     
    Bihua Chen, Managing Member
         
     
    CORMORANT GLOBAL HEALTHCARE GP II, LLC
         
     
    By:
    /s/ Bihua Chen
     
    Bihua Chen, Managing Member
         
     
    CORMORANT ASSET MANAGEMENT, LP
     
    By:
    Cormorant Asset Management GP, LLC
     
     
    its General Partner
     
     
     
     
    By:
    /s/ Bihua Chen
     
    Bihua Chen, Managing Member
     
     
     
     
    /s/ Bihua Chen
     
    Bihua Chen


    Get the next $ALXO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALXO

    DatePrice TargetRatingAnalyst
    11/13/2025$4.00Buy
    Jefferies
    3/6/2025$2.00 → $3.00Hold → Buy
    Jefferies
    12/19/2024$12.00 → $2.00Buy → Hold
    Jefferies
    3/8/2024$10.00 → $14.00Buy → Hold
    Stifel
    12/8/2023$8.00 → $18.00Hold → Buy
    Jefferies
    3/1/2022$60.00 → $36.00Buy
    Stifel
    12/22/2021$65.00 → $25.00Buy → Hold
    Jefferies
    9/30/2021$106.00Buy
    Stifel
    More analyst ratings

    $ALXO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by ALX Oncology Holdings Inc.

    SCHEDULE 13G - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    2/9/26 5:01:43 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by ALX Oncology Holdings Inc.

    SCHEDULE 13D/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    2/4/26 9:03:01 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by ALX Oncology Holdings Inc.

    424B5 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

    1/30/26 4:02:41 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, FINANCE AND CAO Pinto Shelly sold $1,283 worth of shares (565 units at $2.27), decreasing direct ownership by 0.64% to 87,708 units (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/20/26 4:01:02 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Lettmann Jason covered exercise/tax liability with 2,201 shares, decreasing direct ownership by 0.71% to 305,920 units (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/19/26 9:02:25 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Goodman Corey S bought $4,999,999 worth of shares (3,184,713 units at $1.57) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/4/26 4:15:59 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Goodman Corey S bought $4,999,999 worth of shares (3,184,713 units at $1.57) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/4/26 4:15:59 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Lettmann Jason bought $99,352 worth of shares (92,233 units at $1.08), increasing direct ownership by 43% to 305,121 units (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    9/18/25 4:23:19 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Shantharam Harish bought $58,402 worth of shares (75,000 units at $0.78) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    8/20/25 4:02:05 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on ALX Oncology with a new price target

    Jefferies initiated coverage of ALX Oncology with a rating of Buy and set a new price target of $4.00

    11/13/25 9:09:54 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology upgraded by Jefferies with a new price target

    Jefferies upgraded ALX Oncology from Hold to Buy and set a new price target of $3.00 from $2.00 previously

    3/6/25 7:17:16 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology downgraded by Jefferies with a new price target

    Jefferies downgraded ALX Oncology from Buy to Hold and set a new price target of $2.00 from $12.00 previously

    12/19/24 7:28:17 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in the Wells Fargo Executive Biotech Summit, TD Cowen 46th Annual Health Care Conference, and UBS Biotech Summit. The details of the meetings are as follows: Wells Fargo Executive Biotech Summit Format: One-on-one meetingsDate: February 24-25, 2026Location: Lake Tahoe, CA TD Cowen 46th Annual Health Care Conference Format: PresentationDate: March 3, 2026Time: 9:10 AM ESTL

    2/19/26 8:33:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", , NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results press release. Fourth Quarter and Full Year 2025 Results Webcast Information Date & Time: Friday, February 27, 2026 at 5:30am PT / 8:30am ET Webcast Access: https://viavid.webcasts.com/starthere.

    2/19/26 8:30:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology Announces Pricing of Underwritten Offering

    SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (("ALX Oncology, NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the pricing of an underwritten offering of common stock and pre-funded warrants. ALX Oncology is selling 76,979,112 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,574,120 shares of common stock in the offering. The shares of common stock are being sold at an offering price of $1.57 per share, the closing price on January 29, 2026, and the pre-funded warrants are be

    1/30/26 8:30:21 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Leadership Updates

    Live Leadership Updates

    View All

    ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

    Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer Alan Sandler, M.D. resigns as Chief Medical Officer and will return to his position serving on the Company's Board of Directors SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the appointment of Dr. Kl

    9/12/25 8:30:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

    Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operationsDr. Klencke is a seasoned clinical leader in oncology drug development with more than 20 years of industry experienceDr. Takimoto brings a distinguished track record in oncology and drug development with 17 years of industry experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced the appointmen

    1/22/25 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, announced today the appointment of Alan Sandler, M.D., as Chief Medical Officer. "Dr. Sandler's breadth of experience and demonstrated leadership capabilities across oncology and drug development, as well as his in-depth knowledge of ALX Oncology while he was a member of our Board, will be instrumental in helping us achieve our near- and longer-term objectives," said Jason Lettmann, Chief Executive Officer at

    11/14/24 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Financials

    Live finance-specific insights

    View All

    ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", , NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results press release. Fourth Quarter and Full Year 2025 Results Webcast Information Date & Time: Friday, February 27, 2026 at 5:30am PT / 8:30am ET Webcast Access: https://viavid.webcasts.com/starthere.

    2/19/26 8:30:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-09-Breast Cancer trial remains on track for FPI in Q4 2025 and will evaluate evorpacept efficacy by CD47 expression levels Phase 1 trial for ALX2004, a novel EGFR-targeted ADC, is currently enrolling patients in the second dose cohort and on track to deliver initial safety data in 1H 2026 Cash runway expected into Q1 2027 to support key milestones, including ALX2004 initial safety data in 1H 2026, interim data for ASPEN-09-Breast Cancer in Q3 2026 Appointed Board Member Barbara Klencke, M.D.

    11/7/25 8:15:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its third quarter 2025 financial results and provide a business update on Friday, November 7th, 2025, before market open. The company will be hosting a teleconference in conjunction with this press release which will include review of the upcoming data presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting highlighting the full data set demonstrating CD47 overexpressio

    10/30/25 8:30:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 7:22:54 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 6:58:27 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 3:02:41 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care